VSTM News and Press, Verastem Inc. From 01/18/24

2024-01-18 16:28:46 ET More on Verastem Verastem: Potential Accelerated Approval Filing In H1 2024 Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem For further details see: Ve...

Ongoing RAMP 203 Trial Assessing a More Complete Vertical Blockade with RAF/MEK and KRAS G12C Inhibition Along RAS Pathway to Improve Outcomes in KRAS G12C-Mutant NSCLC Confirmed Responses Observed in Both KRAS G12C Inhibitor Naïve and Pre-treated Patients in Initial RAMP 203 Trial R...

2024-01-16 10:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4 th Annual Oncology Conference on Thursday, Janua...

Investigational New Drug (IND) Submission Planned for GFH375/VS-7375 in H1 2024 No FDA Approved Therapies Available Targeting KRAS G12D, the Most Prevalent KRAS Mutation in Human Cancer Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company c...

2023-12-13 12:22:29 ET More on Verastem Verastem: Potential Accelerated Approval Filing In H1 2024 Verastem: Signs Of Life For A Beaten-Down Equity Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial informa...

RAMP 301 Is Evaluating the Combination of Avutometinib and Defactinib vs Investigator’s Choice of Therapy Reported Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination Company Intends ...

2023-11-22 14:22:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through...

2023-11-18 12:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Developed in Partnership with Healthcare Professionals and Patients, Let’s Talk About LGSOC Provides Information Related to the Biology, Diagnosis, Treatment, and Patient Experience Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicine...